CDSCO Ends Emergency-Use Authorization of Baricitinib for COVID-19 Treatment
The Central Drugs Standard Control Organisation (CDSCO) has approved the withdrawal of COVID-19 treatment indications for Baricitinib Tablets.
The withdrawal affects emergency-use authorizations for treating hospitalized COVID-19 patients requiring supplemental oxygen or mechanical ventilation.
These authorizations were issued in May 2021 and November 2021 for Baricitinib, alone or with Remdesivir.
CDSCO has formally approved the withdrawal of COVID-19 treatment indications for Baricitinib Tablets.
Author: CDSCO ends emergency use of Baricitinib for COVID-19.
More News
- Garbage menace and irresponsible behaviour - Star of Mysore
- Instant Reaction: No. 8 Ole Miss defeats No. 13 Oklahoma - HottyToddy.com - Ole Miss Sports, Oxford Entertainment, Dining & More
- Investigation Continues on Explosion that Killed One Person - Door County Pulse
- Raiders welcome Grambling State, Jackson State for HBCU Classic in Las Vegas
- Nobody Wants This' Justine Lupe On Morgan's 'Real Person' Crisis, Relationship With Dr. Andy And Potential Romance With Sasha - TVLine